GSK plc 6-K, filed Oct 27, 2022
GSK plc (GSK)
6-K
2022-10-27
For: 2022-10-27
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on October 27, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of October 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 26 October 2022, London UK
GSK reports outcome from US FDA Advisory Committee meeting on
daprodustat for anaemia of CKD
GSK plc (LSE/NYSE: GSK) today reports that the US Food and Drug
Administration (FDA) Cardiovascular and Renal Drugs Advisory
Committee (CRDAC) supported that the benefit of treatment with
daprodustat outweighs the risks for adult dialysis patients with
anaemia of chronic kidney disease (CKD) with a 13
to 3 vote. In adult non-dialysis patients with anaemia of CKD, the
CRDAC did not support that the benefit of treatment with
daprodustat outweighs the risks with a 5 to 11
vote.
The US FDA will consider the vote, feedback, and recommendations
from the CRDAC as it reviews the New Drug Application (NDA) and is
not bound by the Committee's recommendation. The CRDAC
provides the US FDA with independent, expert advice and reviews and
evaluates available data concerning the safety and efficacy of
marketed and potential new medicines for use in the treatment of
cardiovascular and renal disorders. In April
2022, the US
FDA accepted the NDA for daprodustat and assigned a Prescription
Drug User Fee Act date of 1 February 2023.
CKD is an increasing global health burden affecting 700 million
patients worldwide, with an estimated one in seven patients also
developing anaemia, resulting in increased morbidity, mortality and
reduced quality of life. When not adequately managed in certain
patients, it can result in exhaustion and limit the ability to
function in day-to-day life. When left untreated or undertreated,
anaemia of CKD is associated with poor clinical outcomes and leads
to a substantial burden on patients and healthcare systems. There
remains an unmet need for convenient treatment options with
efficacy and safety comparable to current treatments.
Chris Corsico, Senior Vice President, Development,
GSK, said: "Today's
robust discussion was an important step in the review of
daprodustat. We are pleased the committee recognised the potential
for daprodustat to help certain patients who are living with
anaemia of CKD given limited treatment options. We want to thank
the physicians, patients and advocacy community who shared their
valuable insights about this disease. We look forward to continuing
to work with the US FDA as they complete their review of our new
drug application."
Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase
inhibitor (HIF-PHI), was studied in the ASCEND phase III clinical
trial programme, which included five pivotal trials assessing the
efficacy and safety of daprodustat for the treatment of anaemia
across the spectrum of CKD. All five pivotal trials met the primary
endpoints. Results from two trials were published in
the New
England Journal of Medicine in November 2021,
which included non-dialysis (ASCEND-ND)
and dialysis (ASCEND-D)
CKD patients. Additional results were
also published in the New
England Journal of Medicine supplementary
appendix, which included non-dialysis (ASCEND-ND)
and dialysis (ASCEND-D)
CKD patients.
In March
2022, the
European Medicines Agency validated the marketing authorisation
application for daprodustat, which is currently under regulatory
review, with a regulatory decision anticipated in the first half of
2023. In June
2020, Duvroq (daprodustat)
tablets were approved by Japan's Ministry of Health, Labour and
Welfare for the treatment of patients with anaemia of
CKD. Duvroq is
the market leader and preferred HIF-PHI in
Japan.
About the ASCEND phase III clinical trial programme
The ASCEND programme includes five phase III trials to assess the
efficacy and safety profile of daprodustat for the treatment of
anaemia of CKD across the disease spectrum. The programme enrolled
over 8,000 patients treated for up to 4.26 years. Results from all
five trials were presented at the American Society of Nephrology's
Kidney Week 2021.
Results from the two pivotal cardiovascular outcomes studies,
ASCEND-ND and ASCEND-D, which investigated patients not on dialysis
and on dialysis, respectively, were also published in
the New England Journal of
Medicine[i],[ii]:
● ASCEND-ND (Anaemia
Studies in CKD: Erythropoiesis via a Novel PHI
Daprodustat-Non-Dialysis) enrolled 3,872
non-dialysis dependent patients with anaemia of CKD who were either
switched from the standard of care (ESA) or not currently receiving
ESA therapy to receive daprodustat or ESA control (darbepoetin
alfa). Iron management
protocols were instituted across
both arms of the trial. The trial met its primary efficacy and
safety endpoints. Results showed that daprodustat improved and/or
maintained haemoglobin (Hb) within the target level (10-11.5 g/dL)
for these patients, and the primary safety analysis of the
intention-to-treat (ITT) population showed that daprodustat
achieved
non-inferiority of major adverse
cardiovascular events (MACE) compared to ESA
control.
● ASCEND-D (Anaemia
Studies in CKD: Erythropoiesis via a Novel PHI
Daprodustat-Dialysis) enrolled 2,964 dialysis patients with anaemia
of CKD who were switched to receive daprodustat
or ESA control from a standard of care ESA therapy. A uniform iron
management protocol was instituted across both arms of the trial.
The trial met its primary
efficacy and safety endpoints.
Results showed that daprodustat improved or maintained Hb within
target levels (10-11.5 g/dL) for these patients, and the primary
safety analysis of the ITT population showed that daprodustat
achieved non-inferiority of MACE compared to ESA
control.
Additional results were also published in
the New
England Journal of Medicine supplementary
appendix, which included non-dialysis (ASCEND-ND)
and dialysis (ASCEND-D)
CKD patients.
About anaemia of chronic kidney disease
CKD, characterised by progressive loss of kidney function, is an
increasing global public health burden.[iii] Risk
factors for CKD include hypertension, diabetes, obesity and primary
renal disorders.iii Furthermore,
CKD is an independent risk factor for cardiovascular
disease.iii Anaemia
is an important and frequent complication of
CKD.[iv] However,
it is often poorly diagnosed and undertreated in patients with
early-stage CKD, such as those not on dialysis.iv Over
700 million patients suffer from CKD worldwide, and an estimated
one in seven have anaemia.[v],[vi] When
left untreated or undertreated, anaemia of CKD is associated with
poor clinical outcomes and leads to a substantial burden on
patients and healthcare systems.iv
About daprodustat
Daprodustat, a HIF-PHI, belongs to a novel class of oral medicines
being studied for the treatment of anaemia of CKD in adult
patients not
on dialysis and on dialysis. Inhibition of oxygen-sensing prolyl
hydroxylase enzymes stabilises hypoxia-inducible factors, which can
lead to transcription of erythropoietin and other genes involved in
the correction of anaemia, similar to the physiological effects
that occur in the human body at high altitude. Daprodustat is being
developed to provide a convenient oral treatment option for
patients with anaemia of CKD.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com/company.
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Dan
Smith
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
Lyndsay
Meyer
|
+1 202
302 4595
|
(Washington
DC)
|
|
|
|
|
|
|
Investor
Relations:
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Josh
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK's Q2 Results for 2022 and
any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
[i] Singh
A, et al. Daprodustat for the Treatment of Anemia in Patients Not
Undergoing Dialysis. N Engl J
Med. 2021;
385:2313-2324.
[ii] Singh
A, et al. Daprodustat for the Treatment of Anemia in Patients
Undergoing Dialysis. N Engl J
Med.
2021;385:2325-2335.
[iii]
Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic
kidney disease - A systematic review and
meta-analysis. PLoS
One.
2016;11(7):e0158765.
[iv] St
Peter WL, Guo H, Kabadi S, et al. Prevalence, treatment patterns,
and healthcare resource utilization in Medicare and commercially
insured non-dialysis-dependent chronic kidney disease patients with
and without anemia in the United States. BMC
Nephrol.
2018;19(1):67.
[v] Bikbov
B, Purcell CA, Levey AS, et al. Global, regional, and national
burden of chronic kidney disease, 1990-2017: a systematic analysis
for the Global Burden of Disease Study
2017. Lancet.
2020;395(10225):709-733.
[vi] Stauffer
ME, Fan T. Prevalence of anemia in chronic kidney disease in the
United States. PLoS
One. 2014;9(1):e84943.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: October
27, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|